CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions. About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.
Company Growth (employees)
Type
Public
HQ
Brisbane, US
Size (employees)
55 (est)
CareDx is headquartered in Brisbane, US

CareDx Office Locations

CareDx has office in Brisbane
Brisbane, US

CareDx Metrics

CareDx Summary

Market capitalization

$33.8 m

Closing share price

$1.5
CareDx's current market capitalization is $33.8 m.

CareDx Financials

CareDx's revenue is $27.3 m in FY, 2014
FY, 2014

Revenue

$27.3 m

Gross profit

$18.8 m

Operating expense total

$26.1 m

EBIT

$1.3 m

Net Income

$781 k

Operating cash flow

$31.3 m

CareDx Market Value History

We estimate that CareDx's current employees are approximately 29% female and 71% male.

CareDx Online Presence

CareDx Company Life

You may also be interested in